Inflammatory bowel disease: treatment postulates and future prospects.
Saeed
Sheikh Arshad
SA
Zaidi
Ali Hyder
AH
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000502:physiology; D015195:Drug Design; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000209:etiology*; D016328:NF-kappa B / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D043884:Receptor, Cannabinoid, CB1; D011965:Receptors, Glucocorticoid / Q000502:physiology; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors / Q000502:physiology; D015854:Up-Regulation
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016328:NF-kappa B; D064729:Neurokinin-1 Receptor Antagonists; D043884:Receptor, Cannabinoid, CB1; D011965:Receptors, Glucocorticoid; D018040:Receptors, Neurokinin-1; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human